Login
Subscribe
Take a FREE Trial
About Us
Contact us
RSS
24 May 2013
Search
The Pharma Letter
Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe
Dimebon Articles
Rejected Alzheimer's drug latrepirdine shows new potential in early disease
31 July 2012
Pfizer, Medivation finally pull plug on Dimebon
18 January 2012
Pfizer and Medivation’s Dimebon also flops in Huntington disease
12 April 2011
Medivation persists with Dimebon research in Alzheimer’s, despite earlier failures
8 December 2010
Showing 1-4 of 4 articles
1
Hot Topics
Most Read
Boehringer Ingelheim gets FDA warning letter on cGMP failures
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
Italy's pharma market slump set to continue, warns GlobalData
Is failure to adopt business process management putting the pharma industry at risk?
Boehringer Ingelheim gets FDA warning letter on cGMP failures
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
Italy's pharma market slump set to continue, warns GlobalData
Is failure to adopt business process management putting the pharma industry at risk?